SK1352000A3 - 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor - Google Patents

2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor Download PDF

Info

Publication number: SK1352000A3
Authority: SK; Slovakia
Prior art keywords: disorders; fluoro; piperazin; ylmethyl; hydrogen
Prior art date: 1997-08-15

Application number

SK135-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Anton Franz Josef Fliri

Mark Jerome Majchrzak

Patricia Ann Seymour

Stevin Howard Zorn

Hans Rollema

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-15

Filing date

1998-08-05

Publication date

2000-08-14

1998-08-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2000-08-14 Publication of SK1352000A3 publication Critical patent/SK1352000A3/sk

Links

108090000357 Dopamine D4 receptors Proteins 0.000 title description 2
102000003962 Dopamine D4 receptors Human genes 0.000 title description 2
229940054051 antipsychotic indole derivative Drugs 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 61
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 35
150000003839 salts Chemical class 0.000 claims abstract description 22
229960003638 dopamine Drugs 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
-1 pyridin-2-yl-piperazin-l-ylmethyl Chemical group 0.000 claims description 45
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
208000035475 disorder Diseases 0.000 claims description 31
229910052739 hydrogen Inorganic materials 0.000 claims description 26
239000001257 hydrogen Substances 0.000 claims description 26
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
125000001153 fluoro group Chemical group F* 0.000 claims description 19
241000124008 Mammalia Species 0.000 claims description 17
208000011117 substance-related disease Diseases 0.000 claims description 17
201000009032 substance abuse Diseases 0.000 claims description 16
208000028017 Psychotic disease Diseases 0.000 claims description 15
125000001309 chloro group Chemical group Cl* 0.000 claims description 15
238000000034 method Methods 0.000 claims description 15
229910052757 nitrogen Inorganic materials 0.000 claims description 15
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 12
150000002431 hydrogen Chemical class 0.000 claims description 12
125000004093 cyano group Chemical group *C#N 0.000 claims description 10
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
208000024172 Cardiovascular disease Diseases 0.000 claims description 9
208000018522 Gastrointestinal disease Diseases 0.000 claims description 9
239000000556 agonist Substances 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 9
125000001246 bromo group Chemical group Br* 0.000 claims description 9
206010013663 drug dependence Diseases 0.000 claims description 9
230000000694 effects Effects 0.000 claims description 9
230000002792 vascular Effects 0.000 claims description 9
208000019553 vascular disease Diseases 0.000 claims description 9
208000022873 Ocular disease Diseases 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
208000019116 sleep disease Diseases 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 8
231100000736 substance abuse Toxicity 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 7
101150043870 Drd4 gene Proteins 0.000 claims description 7
208000016285 Movement disease Diseases 0.000 claims description 7
206010047700 Vomiting Diseases 0.000 claims description 6
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
230000008673 vomiting Effects 0.000 claims description 6
208000017194 Affective disease Diseases 0.000 claims description 5
206010019280 Heart failures Diseases 0.000 claims description 5
101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 claims description 5
206010020772 Hypertension Diseases 0.000 claims description 5
201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims description 5
206010043118 Tardive Dyskinesia Diseases 0.000 claims description 5
239000005557 antagonist Substances 0.000 claims description 5
230000027119 gastric acid secretion Effects 0.000 claims description 5
239000003176 neuroleptic agent Substances 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
102100020802 D(1A) dopamine receptor Human genes 0.000 claims description 4
102100020756 D(2) dopamine receptor Human genes 0.000 claims description 4
102000004073 Dopamine D3 Receptors Human genes 0.000 claims description 4
108090000525 Dopamine D3 Receptors Proteins 0.000 claims description 4
101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 claims description 4
101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 claims description 4
208000023105 Huntington disease Diseases 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
MWPFXEHMGAJJCD-UHFFFAOYSA-N 5-fluoro-2-[[4-(4-fluorophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(F)=CC=C1N1CCN(CC=2NC3=CC=C(F)C=C3C=2)CC1 MWPFXEHMGAJJCD-UHFFFAOYSA-N 0.000 claims description 3
102100029813 D(1B) dopamine receptor Human genes 0.000 claims description 3
101000865210 Homo sapiens D(1B) dopamine receptor Proteins 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
HAEDOALGQUCLFO-UHFFFAOYSA-N 2-[[4-(6-chloropyridazin-3-yl)piperazin-1-yl]methyl]-5-fluoro-1h-indole Chemical compound C=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=CC=C(Cl)N=N1 HAEDOALGQUCLFO-UHFFFAOYSA-N 0.000 claims description 2
HHOWJZHPIBYIAE-UHFFFAOYSA-N 2-[[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-1h-indole Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CC=3NC4=CC=CC=C4C=3)CC2)=C1 HHOWJZHPIBYIAE-UHFFFAOYSA-N 0.000 claims description 2
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
PQOIDBZLMJMYCD-UHFFFAOYSA-N 5-fluoro-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-indole Chemical compound C=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 PQOIDBZLMJMYCD-UHFFFAOYSA-N 0.000 claims description 2
YXEZZMBABNHVFB-UHFFFAOYSA-N 5-fluoro-2-[[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-1h-indole Chemical compound C=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 YXEZZMBABNHVFB-UHFFFAOYSA-N 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
239000000460 chlorine Substances 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
102100029815 D(4) dopamine receptor Human genes 0.000 claims 3
208000027465 Psychotic Affective disease Diseases 0.000 claims 1
208000000323 Tourette Syndrome Diseases 0.000 claims 1
239000008186 active pharmaceutical agent Substances 0.000 claims 1
238000004458 analytical method Methods 0.000 description 60
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 33
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 15
JTDKMNZBTHTWKJ-UHFFFAOYSA-N C(C=C/C(=O)O)(=O)O.C(C1=CC=CC=C1)#N Chemical compound C(C=C/C(=O)O)(=O)O.C(C1=CC=CC=C1)#N JTDKMNZBTHTWKJ-UHFFFAOYSA-N 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 10
201000010099 disease Diseases 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
210000002816 gill Anatomy 0.000 description 6
239000007787 solid Substances 0.000 description 6
ZNUQLGRLMDQIID-BTJKTKAUSA-N (Z)-but-2-enedioic acid pyrimidine Chemical compound C1=CN=CN=C1.OC(=O)\C=C/C(O)=O ZNUQLGRLMDQIID-BTJKTKAUSA-N 0.000 description 5
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 5
239000002253 acid Substances 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
LCXSXBYYVYTYDY-BTJKTKAUSA-N (z)-but-2-enedioic acid;piperazine Chemical compound C1CNCCN1.OC(=O)\C=C/C(O)=O LCXSXBYYVYTYDY-BTJKTKAUSA-N 0.000 description 4
QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 4
102000015554 Dopamine receptor Human genes 0.000 description 4
108050004812 Dopamine receptor Proteins 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
239000003880 polar aprotic solvent Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
238000003556 assay Methods 0.000 description 3
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
235000015110 jellies Nutrition 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
239000002674 ointment Substances 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
230000005062 synaptic transmission Effects 0.000 description 3
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
GWTRIXSVMJBFRD-UHFFFAOYSA-N 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-indole Chemical compound C=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 GWTRIXSVMJBFRD-UHFFFAOYSA-N 0.000 description 2
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
SVDHOCZCQXVPOU-UHFFFAOYSA-N 5-fluoro-1h-indole-2-carbaldehyde Chemical compound FC1=CC=C2NC(C=O)=CC2=C1 SVDHOCZCQXVPOU-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
229910004298 SiO 2 Inorganic materials 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
150000007514 bases Chemical class 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 2
CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000003137 locomotive effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002609 medium Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
GIPXMXAYTYHIKL-UHFFFAOYSA-N (5-fluoro-1h-indol-2-yl)-(4-pyridin-2-ylpiperazin-1-yl)methanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(=O)N(CC1)CCN1C1=CC=CC=N1 GIPXMXAYTYHIKL-UHFFFAOYSA-N 0.000 description 1
ONCQOAGPACYSDJ-UHFFFAOYSA-N (5-fluoro-1h-indol-2-yl)-[4-(2-nitrophenyl)piperazin-1-yl]methanone Chemical compound [O-][N+](=O)C1=CC=CC=C1N1CCN(C(=O)C=2NC3=CC=C(F)C=C3C=2)CC1 ONCQOAGPACYSDJ-UHFFFAOYSA-N 0.000 description 1
TZQTUVKKDQHARM-UHFFFAOYSA-N (5-fluoro-1h-indol-2-yl)-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methanone Chemical compound C=1C2=CC(F)=CC=C2NC=1C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 TZQTUVKKDQHARM-UHFFFAOYSA-N 0.000 description 1
NWPYAKWXPBVIDT-BTJKTKAUSA-N (z)-but-2-enedioic acid;isoindole-1,3-dione Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=C2C(=O)NC(=O)C2=C1 NWPYAKWXPBVIDT-BTJKTKAUSA-N 0.000 description 1
VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
FISMTDVFYIMUBI-UHFFFAOYSA-N 1h-indol-2-yl-(4-pyridin-2-ylpiperazin-1-yl)methanone Chemical compound C=1C2=CC=CC=C2NC=1C(=O)N(CC1)CCN1C1=CC=CC=N1 FISMTDVFYIMUBI-UHFFFAOYSA-N 0.000 description 1
RXFRHGBGKRBRJO-UHFFFAOYSA-N 1h-indol-2-yl-[4-(2-nitrophenyl)piperazin-1-yl]methanone Chemical compound [O-][N+](=O)C1=CC=CC=C1N1CCN(C(=O)C=2NC3=CC=CC=C3C=2)CC1 RXFRHGBGKRBRJO-UHFFFAOYSA-N 0.000 description 1
NRZMEMYHVIKKHS-UHFFFAOYSA-N 2-[(4-naphthalen-1-ylpiperazin-1-yl)methyl]-1h-indole Chemical compound C1=CC=C2NC(CN3CCN(CC3)C=3C4=CC=CC=C4C=CC=3)=CC2=C1 NRZMEMYHVIKKHS-UHFFFAOYSA-N 0.000 description 1
PZTWBYCZTVLVPV-UHFFFAOYSA-N 2-[2-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCCC1CNCCN1CCS(O)(=O)=O PZTWBYCZTVLVPV-UHFFFAOYSA-N 0.000 description 1
CWQOSWBNXOLUEQ-UHFFFAOYSA-N 2-[[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-1h-indol-5-ol Chemical compound C=1C2=CC(O)=CC=C2NC=1CN(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 CWQOSWBNXOLUEQ-UHFFFAOYSA-N 0.000 description 1
UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
JYJAHLMLMXZTEH-UHFFFAOYSA-N 3-[4-(1h-indol-2-ylmethyl)piperazin-1-yl]-1,2-benzothiazole Chemical compound C1=CC=C2NC(CN3CCN(CC3)C=3C4=CC=CC=C4SN=3)=CC2=C1 JYJAHLMLMXZTEH-UHFFFAOYSA-N 0.000 description 1
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
WTXBRZCVLDTWLP-UHFFFAOYSA-N 5-fluoro-1H-indole-2-carboxylic acid Chemical compound FC1=CC=C2NC(C(=O)O)=CC2=C1 WTXBRZCVLDTWLP-UHFFFAOYSA-N 0.000 description 1
UMLGAJBWICWJOR-UHFFFAOYSA-N 5-fluoro-1h-indole-2-carbonyl chloride Chemical compound FC1=CC=C2NC(C(Cl)=O)=CC2=C1 UMLGAJBWICWJOR-UHFFFAOYSA-N 0.000 description 1
WZACPVLYMQHASB-UHFFFAOYSA-N 5-fluoro-2-[(4-naphthalen-1-ylpiperazin-1-yl)methyl]-1h-indole Chemical compound C1=CC=C2C(N3CCN(CC3)CC=3NC4=CC=C(C=C4C=3)F)=CC=CC2=C1 WZACPVLYMQHASB-UHFFFAOYSA-N 0.000 description 1
XFARCYFOVVDEHP-UHFFFAOYSA-N 5-fluoro-2-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]-1h-indole Chemical compound C=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=NC=CC=N1 XFARCYFOVVDEHP-UHFFFAOYSA-N 0.000 description 1
QSBOGUJMCZHCOI-UHFFFAOYSA-N 5-fluoro-2-[[4-(2-nitrophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound [O-][N+](=O)C1=CC=CC=C1N1CCN(CC=2NC3=CC=C(F)C=C3C=2)CC1 QSBOGUJMCZHCOI-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
SOZLXJPONQTIIL-UCZKPGLMSA-N C1CN(C(CN1)/C(=C/C(=O)O)/C(=O)O)/C(=C/C(=O)O)/C(=O)O Chemical compound C1CN(C(CN1)/C(=C/C(=O)O)/C(=O)O)/C(=C/C(=O)O)/C(=O)O SOZLXJPONQTIIL-UCZKPGLMSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241001342895 Chorus Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
208000020358 Learning disease Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
101100327347 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDD1 gene Proteins 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000005910 alkyl carbonate group Chemical group 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
MIHBFANPMPEZEI-UHFFFAOYSA-N benzonitrile dihydrochloride Chemical compound Cl.Cl.N#CC1=CC=CC=C1 MIHBFANPMPEZEI-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
239000012267 brine Substances 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
208000026735 cervix disease Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229940126513 cyclase activator Drugs 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
HAORKNGNJCEJBX-UHFFFAOYSA-N cyprodinil Chemical compound N=1C(C)=CC(C2CC2)=NC=1NC1=CC=CC=C1 HAORKNGNJCEJBX-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
229940005501 dopaminergic agent Drugs 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000028993 immune response Effects 0.000 description 1
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
201000003723 learning disability Diseases 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
229950001037 quinpirole Drugs 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000009329 sexual behaviour Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

SK135-2000A 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor SK1352000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5576497P	1997-08-15	1997-08-15
PCT/IB1998/001198 WO1999009025A2 (fr)	1997-08-15	1998-08-05	Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole

Publications (1)

Publication Number	Publication Date
SK1352000A3 true SK1352000A3 (en)	2000-08-14

Family

ID=22000003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK135-2000A SK1352000A3 (en)	1997-08-15	1998-08-05	2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor

Country Status (30)

Country	Link
EP (1)	EP1003739A2 (fr)
JP (1)	JP2002536291A (fr)
KR (1)	KR20010022507A (fr)
CN (1)	CN1265660A (fr)
AP (1)	AP9801321A0 (fr)
AR (1)	AR017019A1 (fr)
AU (1)	AU8457298A (fr)
BG (1)	BG104069A (fr)
BR (1)	BR9811557A (fr)
CA (1)	CA2297486C (fr)
CO (1)	CO4960656A1 (fr)
DZ (1)	DZ2583A1 (fr)
EA (1)	EA200000023A1 (fr)
HR (1)	HRP980441A2 (fr)
HU (1)	HUP0003425A3 (fr)
ID (1)	ID23803A (fr)
IL (1)	IL133960A0 (fr)
IS (1)	IS5336A (fr)
MA (1)	MA24632A1 (fr)
NO (1)	NO20000722L (fr)
OA (1)	OA11286A (fr)
PA (1)	PA8457001A1 (fr)
PE (1)	PE106299A1 (fr)
PL (1)	PL338947A1 (fr)
SK (1)	SK1352000A3 (fr)
TN (1)	TNSN98151A1 (fr)
TR (1)	TR200000414T2 (fr)
UY (1)	UY25144A1 (fr)
WO (1)	WO1999009025A2 (fr)
ZA (1)	ZA987304B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2205179C2 (ru) *	1997-10-27	2003-05-27	НьюроСёрч А/С	Производное гомопиперазина и фармацевтическая композиция
EP0953567A3 (fr) *	1998-04-29	2003-04-02	Pfizer Products Inc.	Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
IL150366A0 (en) *	1999-12-30	2002-12-01	Lundbeck & Co As H	4-phenyl-1-piperazinyl,-piperidinyl and tetrahydropyridyl derivatives
GB0017952D0 (en) *	2000-07-22	2000-09-13	Univ Manchester	Treatment of dyskinesia
EP1177792A3 (fr)	2000-07-27	2002-10-23	Pfizer Products Inc.	Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
CA2440438C (fr) *	2001-03-09	2011-05-03	Ortho-Mcneil Pharmaceutical, Inc.	Composes heterocycliques
UA79309C2 (en)	2002-09-06	2007-06-11	Janssen Pharmaceutica Nv	Heterocyclic compounds
WO2004108671A1 (fr) *	2003-06-06	2004-12-16	Suven Life Sciences Limited	Indoles substitues dotes d'une affinite pour le recepteur de la serotonine, leur procede de fabrication et compositions pharmaceutiques les contenant
EP1731505B1 (fr)	2004-03-30	2015-01-14	Takeda Pharmaceutical Company Limited	Dérivés de l'acide alkoxyphénylpropanoïque
US7618980B2 (en)	2004-07-14	2009-11-17	Bristol-Myers Squibb Company	Pyrrolo(oxo)quinolines as 5HT ligands
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
JO2769B1 (en) *	2005-10-26	2014-03-15	جانسين فارماسوتيكا ان. في	Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en) *	2006-12-08	2012-06-17	جانسين فارماسوتيكا ان. في	Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) *	2007-02-13	2015-03-15	جانسين فارماسوتيكا ان. في	Dopamine 2 receptor antagonists are rapidly hydrolyzed
RS52518B (en)	2007-04-23	2013-04-30	Janssen Pharmaceutica N.V.	4-ALCOXYPYRIDASINE DERIVATIVES AS A FAST DISSOCATING DOPAMINE 2 RECEPTOR ANTAGONISTS
CA2682671C (fr)	2007-04-23	2015-11-17	Janssen Pharmaceutica N.V.	Thia(dia)zoles en tant qu'antagonistes du recepteur de la dopamine a dissociation rapide
CA2729313C (fr)	2008-07-03	2016-08-30	Janssen Pharmaceutica Nv	6-(1-piperazinyl)-pyridazines substituees comme antagonistes du recepteur 5-ht<sb>6</sb>
EA019048B1 (ru)	2008-07-31	2013-12-30	Янссен Фармацевтика Нв	Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d-рецепторов дофамина
EP3686196B1 (fr) *	2017-09-20	2024-06-12	Hangzhou Innogate Pharma Co., Ltd.	Composé polycyclique agissant en tant qu'inhibiteur de l'ido et/ou en tant qu'inhibiteur double de l'ido-hdac
WO2021216665A1 (fr) *	2020-04-22	2021-10-28	Anima Biotech Inc.	Inhibiteurs de traduction de collagène 1 et leurs procédés d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB944443A (fr) *	1959-09-25	1900-01-01
JP3119485B2 (ja) *	1991-07-03	2000-12-18	ファルマシア・アンド・アップジョン・カンパニー	抗−エイズ薬としての置換インドール類
JPH05255089A (ja) *	1991-12-18	1993-10-05	Sanwa Kagaku Kenkyusho Co Ltd	抗ウイルス剤
EP0665840A1 (fr) *	1992-10-23	1995-08-09	MERCK SHARP & DOHME LTD.	Ligands pour les sous-types de recepteurs de dopamine
GB9305644D0 (en) *	1993-03-18	1993-05-05	Merck Sharp & Dohme	Therapeutic agents
WO1994021627A1 (fr) *	1993-03-18	1994-09-29	Merck Sharp & Dohme Limited	Derives indoliques servant d'antagonistes de dopamine d4
WO1994024105A1 (fr) *	1993-04-15	1994-10-27	Merck Sharp & Dohme Limited	Derives d'indole utiles comme antagonistes de la dopamine d4
DE4414113A1 (de) *	1994-04-22	1995-10-26	Merck Patent Gmbh	3-Indolylpiperidine
TW406075B (en) *	1994-12-13	2000-09-21	Upjohn Co	Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
ZA968661B (en) *	1995-11-17	1998-04-14	Upjohn Co	Oxazolidinone antibacterial agent with tricyclic substituents.
TW504510B (en) *	1996-05-10	2002-10-01	Janssen Pharmaceutica Nv	2,4-diaminopyrimidine derivatives

1998
- 1998-08-05 KR KR1020007001093A patent/KR20010022507A/ko not_active Ceased
- 1998-08-05 ID IDW20000197A patent/ID23803A/id unknown
- 1998-08-05 WO PCT/IB1998/001198 patent/WO1999009025A2/fr not_active Application Discontinuation
- 1998-08-05 AU AU84572/98A patent/AU8457298A/en not_active Abandoned
- 1998-08-05 CA CA002297486A patent/CA2297486C/fr not_active Expired - Fee Related
- 1998-08-05 EA EA200000023A patent/EA200000023A1/ru unknown
- 1998-08-05 SK SK135-2000A patent/SK1352000A3/sk unknown
- 1998-08-05 HU HU0003425A patent/HUP0003425A3/hu unknown
- 1998-08-05 AP APAP/P/1998/001321A patent/AP9801321A0/en unknown
- 1998-08-05 CN CN98807831A patent/CN1265660A/zh active Pending
- 1998-08-05 IL IL13396098A patent/IL133960A0/xx unknown
- 1998-08-05 PL PL98338947A patent/PL338947A1/xx unknown
- 1998-08-05 JP JP2000509706A patent/JP2002536291A/ja active Pending
- 1998-08-05 BR BR9811557-0A patent/BR9811557A/pt not_active IP Right Cessation
- 1998-08-05 TR TR2000/00414T patent/TR200000414T2/xx unknown
- 1998-08-05 EP EP98935229A patent/EP1003739A2/fr not_active Withdrawn
- 1998-08-10 PA PA19988457001A patent/PA8457001A1/es unknown
- 1998-08-10 PE PE1998000717A patent/PE106299A1/es not_active Application Discontinuation
- 1998-08-12 TN TNTNSN98151A patent/TNSN98151A1/fr unknown
- 1998-08-12 DZ DZ980193A patent/DZ2583A1/fr active
- 1998-08-12 MA MA25210A patent/MA24632A1/fr unknown
- 1998-08-13 AR ARP980104021A patent/AR017019A1/es unknown
- 1998-08-14 CO CO98046788A patent/CO4960656A1/es unknown
- 1998-08-14 ZA ZA9807304A patent/ZA987304B/xx unknown
- 1998-08-14 HR HR60/055,764A patent/HRP980441A2/hr not_active Application Discontinuation
- 1998-08-17 UY UY25144A patent/UY25144A1/es not_active Application Discontinuation
2000
- 2000-01-10 BG BG104069A patent/BG104069A/xx unknown
- 2000-01-11 IS IS5336A patent/IS5336A/is unknown
- 2000-02-08 OA OA1200000030A patent/OA11286A/en unknown
- 2000-02-14 NO NO20000722A patent/NO20000722L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HRP980441A2 (en)	1999-04-30
JP2002536291A (ja)	2002-10-29
ZA987304B (en)	2000-02-14
AU8457298A (en)	1999-03-08
TNSN98151A1 (fr)	2005-03-15
EP1003739A2 (fr)	2000-05-31
ID23803A (id)	2000-05-11
AP9801321A0 (en)	2000-02-14
NO20000722D0 (no)	2000-02-14
PE106299A1 (es)	1999-11-02
DZ2583A1 (fr)	2003-02-22
MA24632A1 (fr)	1999-04-01
BG104069A (en)	2001-05-31
WO1999009025A2 (fr)	1999-02-25
EA200000023A1 (ru)	2000-08-28
IL133960A0 (en)	2001-04-30
HUP0003425A3 (en)	2002-02-28
CO4960656A1 (es)	2000-09-25
PL338947A1 (en)	2000-12-04
CA2297486C (fr)	2005-05-03
CN1265660A (zh)	2000-09-06
BR9811557A (pt)	2000-08-22
WO1999009025A3 (fr)	1999-04-15
IS5336A (is)	2000-01-11
OA11286A (en)	2003-10-22
KR20010022507A (ko)	2001-03-15
CA2297486A1 (fr)	1999-02-25
PA8457001A1 (es)	2000-09-29
TR200000414T2 (tr)	2000-08-21
NO20000722L (no)	2000-02-14
AR017019A1 (es)	2001-08-22
UY25144A1 (es)	2000-12-29
HUP0003425A2 (hu)	2001-10-28

Publication	Publication Date	Title
SK1352000A3 (en)	2000-08-14	2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
US6521623B1 (en)	2003-02-18	N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en)	2003-07-01	Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US5681956A (en)	1997-10-28	4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
KR20130136010A (ko)	2013-12-11	Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물
BRPI0616575A2 (pt)	2011-06-21	compostos e composições contendo diarilamina, seu uso como moduladores de receptores de c-kit bem como método para sua produção
NZ520342A (en)	2004-08-27	1,3-Disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
AU765317B2 (en)	2003-09-18	4,5,6 and 7-indole and indoline derivatives, their preparation and use
CA2066332C (fr)	2003-07-29	Derives de substitution de 3-(pyridinylamino)indoles et de benzo¬b\|thiophenes; methode de preparation et utilisation comme medicaments
US7544685B2 (en)	2009-06-09	2,3-dihydroindole compounds
Andersen et al.	1992	Selective, centrally acting serotonin 5-HT2 antagonists. 2. Substituted 3-(4-fluorophenyl)-1H-indoles
Wustrow et al.	1998	Aminopyrimidines with high affinity for both serotonin and dopamine receptors
AU2002300094B2 (en)	2007-06-14	New octahydro-2H-pyrido[1,2-alpha]pyrazine compounds, a process for their preparation and pharmaceutical compositions containing them
CA2417081C (fr)	2008-08-05	Derives benzimidazolone n,n'-disubstitues presentant une affinite pour les recepteurs de la serotonine et de la dopamine
US20040198734A1 (en)	2004-10-07	2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine
HUP0301735A2 (hu)	2003-08-28	A központi idegrendszer megbetegedéseinek kezelésére alkalmas indolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JP2009504691A (ja)	2009-02-05	新規２，３−ジヒドロインドール化合物
Balle et al.	2003	Synthesis and structure–affinity relationship investigations of 5-aminomethyl and 5-carbamoyl analogues of the antipsychotic sertindole. A new class of selective α1 adrenoceptor antagonists
US6031097A (en)	2000-02-29	1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
JP2014518257A (ja)	2014-07-28	中枢神経系疾患の処置のためのインドールアミン誘導体
SK19412000A3 (sk)	2001-07-10	Substituované 4,5,6 a 7-indolové alebo indolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
CZ2000307A3 (cs)	2000-08-16	Deriváty 2-(4-aryI nebo heteroarylpiperazin-1- ylmetyl)-lH-indolu
MXPA01012449A (es)	2002-06-11	Derivados de acilaminciclopropano.
MXPA00001611A (en)	2001-03-05	2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
US7371769B2 (en)	2008-05-13	Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites